Journal
CURRENT ONCOLOGY REPORTS
Volume 22, Issue 3, Pages -Publisher
SPRINGER
DOI: 10.1007/s11912-020-0886-z
Keywords
Immune checkpoint inhibitors; Programmed death-1 (PD-1); Programmed death ligand-1 (PD-L1); Exhausted T cells (Tex); Tumor microenvironment (TME); Memory T cells (Tmem); Tumor mutation burden; Circulating tumor DNA
Categories
Ask authors/readers for more resources
Purpose of Review Recent developments in immunotherapy have transformed the landscape of melanoma therapy. Here, we review markers for response to immunotherapy. Recent Findings Current immunotherapies disable immune checkpoints on T cells and other immune cells and allow immune rejection of tumor. This process depends crucially on a preexisting response to the development of the melanoma. Here we describe the complexity of the anti-tumor immune response and the links to the development of markers that are currently used or under investigation in the clinic. We describe immune response biomarkers along with new developments that could translate into advances.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available